XML 46 R35.htm IDEA: XBRL DOCUMENT v3.7.0.1
Collaboration and Licensing Agreements (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Jul. 31, 2016
USD ($)
Jun. 30, 2016
USD ($)
product
item
Sep. 30, 2015
USD ($)
item
Dec. 31, 2014
USD ($)
Jul. 31, 2013
USD ($)
item
Jan. 31, 2013
USD ($)
item
Feb. 28, 2009
item
Mar. 31, 2017
USD ($)
item
Mar. 31, 2016
USD ($)
Dec. 31, 2016
USD ($)
item
Collaboration research and licensing agreements                        
Revenue recognized                   $ 4,340,000 $ 7,252,000  
Current portion of deferred revenue $ 95,788,000 $ 95,521,000               95,788,000   $ 95,521,000
License Agreement | Merck Sharp & Dohme Corp.                        
Collaboration research and licensing agreements                        
Nonrefundable upfront payment             $ 1,000,000          
Annual maintenance fees             $ 500,000          
Revenue recognized                   25,000 25,000  
Deferred revenue 25,000                 25,000    
Number of compounds | item             1          
Portion of nonrefundable upfront payment allocated to option             $ 0          
License Agreement | Alexion Pharmaceuticals, Inc.                        
Collaboration research and licensing agreements                        
Nonrefundable upfront payment                   2,500,000    
Research term of revenue recognized               5 years        
Option and license agreement | Alexion Pharmaceuticals, Inc.                        
Collaboration research and licensing agreements                        
Nonrefundable upfront payment               $ 3,000,000        
Milestone payment   $ 5,000,000                    
Number of different target programs | item               6        
Research license term               5 years        
Annual maintenance fees               $ 500,000        
Revenue recognized                   250,000 250,000  
Deferred revenue 800,000                 $ 800,000    
Additional research term                   3 years    
Extension fee                   $ 2,000,000    
Annual maintenance fees payable during any extension of research term               $ 1,000,000        
2009 Research License and Commercialization Agreement                        
Collaboration research and licensing agreements                        
Number of commercial licenses | item                 1      
2009 Research License and Commercialization Agreement | CSL Limited                        
Collaboration research and licensing agreements                        
Milestone payment 3,500,000                      
Revenue recognized                   3,500,000 0  
Deferred revenue 0                 0    
Collaboration And License Agreement | Novartis                        
Collaboration research and licensing agreements                        
Nonrefundable upfront payment     $ 150,000,000                  
Revenue recognized                   600,000 0  
Deferred revenue 89,700,000                 89,700,000    
Collaboration And License Agreement | Novartis | Maximum                        
Collaboration research and licensing agreements                        
Potential milestone payment                   $ 2,400,000,000    
Collaboration And License Agreement | Novartis | Bispecific FC Technologies                        
Collaboration research and licensing agreements                        
Number of development stage products | product       2                
Collaboration And License Agreement | Novartis | Bispecific FC Technologies | XmAb14045                        
Collaboration research and licensing agreements                        
Allocation of consideration to deliverables       $ 27,100,000                
Collaboration And License Agreement | Novartis | Bispecific FC Technologies | XmAb13676                        
Collaboration research and licensing agreements                        
Allocation of consideration to deliverables       31,400,000                
Collaboration And License Agreement | Novartis | Global Discovery Program                        
Collaboration research and licensing agreements                        
Number of bispecific product candidates delivered | item                   0    
Allocation of consideration to deliverables       $ 20,050,000                
Number of Global discovery programs | item       4                
Collaboration And License Agreement | Novartis | Global Discovery Program | Maximum                        
Collaboration research and licensing agreements                        
Number of antibody targets for which bispecific technology applied | item       4                
Collaboration And License Agreement | Novartis | FC Licenses                        
Collaboration research and licensing agreements                        
Research license term                   5 years    
Number of bispecific product candidates delivered | product       4                
Allocation of consideration to deliverables       $ 11,300,000                
Collaboration And License Agreement | Novartis | FC Licenses | Maximum                        
Collaboration research and licensing agreements                        
Number of targets against which non-exclusive license is provided | item       10                
Collaboration And License Agreement | Novo Nordisk                        
Collaboration research and licensing agreements                        
Nonrefundable upfront payment           $ 2,500,000            
Research license term           2 years            
Revenue recognized                   $ 0 700,000  
Deferred revenue 0                 $ 0    
Research term of revenue recognized           2 years            
Research and License Agreement 2015 | Amgen, Inc.                        
Collaboration research and licensing agreements                        
Nonrefundable upfront payment         $ 45,000,000              
Potential milestone payment         $ 1,700,000,000              
Number of different target programs | item         6              
Number of previously identified products | item                   3    
Number of bispecific product candidates delivered | item                   0    
Substituted candidates | item                   0    
Revenue recognized                   $ 0 $ 6,250,000  
Deferred revenue $ 12,500,000                 12,500,000    
Research and License Agreement 2015 | Amgen, Inc. | CD38 Program                        
Collaboration research and licensing agreements                        
Potential milestone payment                   355,000,000    
Allocation of consideration to deliverables                   13,750,000    
Research and License Agreement 2015 | Amgen, Inc. | Discovery Program                        
Collaboration research and licensing agreements                        
Potential milestone payment                   $ 260,500,000    
Research license term                   3 years    
Allocation of consideration to deliverables                   $ 6,250,000    
Additional research term                   1 year    
Previous targets which bispecific technology will be applied | item         5              
Research and License Agreement 2015 | Amgen, Inc. | Global Discovery Program                        
Collaboration research and licensing agreements                        
Number of different target programs | item                       3
Number of bispecific product candidates delivered | item                       5
Substituted candidates | item                       1
Development-based | Research and License Agreement 2015 | Amgen, Inc. | CD38 Program                        
Collaboration research and licensing agreements                        
Potential milestone payment                   $ 55,000,000    
Development-based | Research and License Agreement 2015 | Amgen, Inc. | Discovery Program                        
Collaboration research and licensing agreements                        
Potential milestone payment                   35,500,000    
Regulatory-based | Research and License Agreement 2015 | Amgen, Inc. | CD38 Program                        
Collaboration research and licensing agreements                        
Potential milestone payment                   70,000,000    
Regulatory-based | Research and License Agreement 2015 | Amgen, Inc. | Discovery Program                        
Collaboration research and licensing agreements                        
Potential milestone payment                   55,000,000    
Sales-based | Research and License Agreement 2015 | Amgen, Inc. | CD38 Program                        
Collaboration research and licensing agreements                        
Potential milestone payment                   230,000,000    
Sales-based | Research and License Agreement 2015 | Amgen, Inc. | Discovery Program                        
Collaboration research and licensing agreements                        
Potential milestone payment                   $ 170,000,000